Precipio (PRPO)
Market Price (7/13/2026): $24.39 | Market Cap: $43.5 MilSector: Health Care | Industry: Life Sciences Tools & Services
Precipio (PRPO)
Market Price (7/13/2026): $24.39Market Cap: $43.5 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Personalized Diagnostics, Advanced Diagnostics, Show more. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -1.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.9% Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 54x Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.5% Key risksPRPO key risks include [1] its history of operating losses creating significant doubt about its ability to continue as a going concern and [2] challenges in securing adequate reimbursement for its diagnostic products. |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Personalized Diagnostics, Advanced Diagnostics, Show more. |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -1.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -6.9% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 54x |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.5% |
| Key risksPRPO key risks include [1] its history of operating losses creating significant doubt about its ability to continue as a going concern and [2] challenges in securing adequate reimbursement for its diagnostic products. |
Qualitative Assessment
AI Analysis | Feedback
Precipio (PRPO) stock has lost about 5% since 3/31/2026 because of the following key factors:
1. Precipio reported a widened net loss and a significant decline in Adjusted EBITDA for fiscal Q1 2026, which ended on March 31, 2026. The company announced a net loss of -$1.44 million, a notable deterioration from -$0.9 million in fiscal Q1 2025 and a substantial drop from the trailing 12 months ending March 31, 2026, which saw a net loss of -$922.0k. Additionally, Adjusted EBITDA fell to -$0.16 million in fiscal Q1 2026, a decrease from $0.96 million in fiscal Q4 2025.
2. The company's fiscal Q1 2026 financial performance was negatively impacted by a reduction in CMS fees and temporary delays in product revenue. An 8% reduction in the Centers for Medicare & Medicaid Services (CMS) fee for flow cytometry, a frequently used test, resulted in an approximate $0.5 million write-down in revenue and affected gross margins. Concurrently, product revenue decreased by $80,000 from fiscal Q4 2025 to fiscal Q1 2026, as a significant customer order was shifted from late Q1 to early fiscal Q2 2026, affecting revenue recognition.
Show more
Precipio (PRPO) stock has lost about 5% since 3/31/2026 because of the following key factors:
1. Precipio reported a widened net loss and a significant decline in Adjusted EBITDA for fiscal Q1 2026, which ended on March 31, 2026. The company announced a net loss of -$1.44 million, a notable deterioration from -$0.9 million in fiscal Q1 2025 and a substantial drop from the trailing 12 months ending March 31, 2026, which saw a net loss of -$922.0k. Additionally, Adjusted EBITDA fell to -$0.16 million in fiscal Q1 2026, a decrease from $0.96 million in fiscal Q4 2025.
2. The company's fiscal Q1 2026 financial performance was negatively impacted by a reduction in CMS fees and temporary delays in product revenue. An 8% reduction in the Centers for Medicare & Medicaid Services (CMS) fee for flow cytometry, a frequently used test, resulted in an approximate $0.5 million write-down in revenue and affected gross margins. Concurrently, product revenue decreased by $80,000 from fiscal Q4 2025 to fiscal Q1 2026, as a significant customer order was shifted from late Q1 to early fiscal Q2 2026, affecting revenue recognition.
3. Increased operating expenses contributed to the reduced profitability in fiscal Q1 2026. Precipio experienced a $250,000 impact from increased costs associated with hiring a new product business development team. This was exacerbated by the absence of a one-time benefit recorded in fiscal Q4 2025, which included a reversal of management annual bonus accruals amounting to approximately $360,000.
4. Analyst forecasts and price targets indicated a significantly more bearish outlook than the stock's prevailing price. On May 2, 2026, one analyst raised their price target to $7.00 from $5.15, which, while an increase, remained substantially below the stock's trading levels. Moreover, other analyst projections for Precipio in 2026 suggested an average price target around $4.56, indicating a potential downside of over 80% from recent prices of around $24.93, contributing to negative investor sentiment.
5. Concerns regarding corporate governance or shareholder engagement arose due to difficulties in achieving a quorum for the Annual Meeting in June 2026. Precipio issued an urgent request to shareholders on June 12, 2026, to vote immediately for the Annual Meeting scheduled for June 15, 2026. This was necessary to meet the minimum 50% quorum requirement, as only about 42% of shares had been voted at the time, to avoid costly adjournment and rescheduling.
Show less
Stock Movement Drivers
Fundamental Drivers
The -4.8% change in PRPO stock from 3/31/2026 to 7/12/2026 was primarily driven by a -10.4% change in the company's P/S Multiple.| (LTM values as of) | 3312026 | 7122026 | Change |
|---|---|---|---|
| Stock Price ($) | 25.00 | 23.80 | -4.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 24 | 26 | 7.4% |
| P/S Multiple | 1.8 | 1.6 | -10.4% |
| Shares Outstanding (Mil) | 2 | 2 | -1.1% |
| Cumulative Contribution | -4.8% |
Market Drivers
3/31/2026 to 7/12/2026| Return | Correlation | |
|---|---|---|
| PRPO | -4.8% | |
| Market (SPY) | 16.1% | 8.2% |
| Sector (XLV) | 9.7% | 16.6% |
Fundamental Drivers
The 3.6% change in PRPO stock from 12/31/2025 to 7/12/2026 was primarily driven by a 13.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 12312025 | 7122026 | Change |
|---|---|---|---|
| Stock Price ($) | 22.98 | 23.80 | 3.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 23 | 26 | 13.3% |
| P/S Multiple | 1.7 | 1.6 | -0.5% |
| Shares Outstanding (Mil) | 2 | 2 | -8.2% |
| Cumulative Contribution | 3.6% |
Market Drivers
12/31/2025 to 7/12/2026| Return | Correlation | |
|---|---|---|
| PRPO | 3.6% | |
| Market (SPY) | 11.0% | 10.0% |
| Sector (XLV) | 4.3% | 7.2% |
Fundamental Drivers
The 115.6% change in PRPO stock from 6/30/2025 to 7/12/2026 was primarily driven by a 98.4% change in the company's P/S Multiple.| (LTM values as of) | 6302025 | 7122026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.04 | 23.80 | 115.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 20 | 26 | 29.0% |
| P/S Multiple | 0.8 | 1.6 | 98.4% |
| Shares Outstanding (Mil) | 2 | 2 | -15.7% |
| Cumulative Contribution | 115.6% |
Market Drivers
6/30/2025 to 7/12/2026| Return | Correlation | |
|---|---|---|
| PRPO | 115.6% | |
| Market (SPY) | 23.2% | 3.1% |
| Sector (XLV) | 20.9% | 5.7% |
Fundamental Drivers
The 205.1% change in PRPO stock from 6/30/2023 to 7/12/2026 was primarily driven by a 164.1% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 6302023 | 7122026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.80 | 23.80 | 205.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 10 | 26 | 164.1% |
| P/S Multiple | 0.9 | 1.6 | 77.5% |
| Shares Outstanding (Mil) | 1 | 2 | -34.9% |
| Cumulative Contribution | 205.1% |
Market Drivers
6/30/2023 to 7/12/2026| Return | Correlation | |
|---|---|---|
| PRPO | 205.1% | |
| Market (SPY) | 76.3% | 4.8% |
| Sector (XLV) | 26.9% | 4.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PRPO Return | -24% | -65% | -41% | -15% | 315% | 15% | -36% |
| Peers Return | 16% | -55% | 18% | -9% | 39% | 12% | -13% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| PRPO Win Rate | 33% | 33% | 17% | 42% | 75% | 71% | |
| Peers Win Rate | 43% | 32% | 47% | 43% | 50% | 57% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 57% | |
Max Drawdowns [4] | |||||||
| PRPO Max Drawdown | -70% | -71% | -73% | -36% | -56% | -32% | |
| Peers Max Drawdown | -43% | -60% | -40% | -36% | -44% | -44% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: NEO, FLGT, MYGN, GH, QGEN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/10/2026 (YTD)
How Low Can It Go
| Event | PRPO | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -45.9% | -18.8% |
| % Gain to Breakeven | 84.8% | 23.1% |
| Time to Breakeven | 42 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -18.7% | -9.5% |
| % Gain to Breakeven | 22.9% | 10.5% |
| Time to Breakeven | 14 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -59.9% | -6.7% |
| % Gain to Breakeven | 149.3% | 7.1% |
| Time to Breakeven | 800 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -65.9% | -33.7% |
| % Gain to Breakeven | 193.1% | 50.9% |
| Time to Breakeven | 114 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -62.0% | -19.2% |
| % Gain to Breakeven | 163.4% | 23.8% |
| Time to Breakeven | 109 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -92.6% | -3.7% |
| % Gain to Breakeven | 1243.3% | 3.9% |
| Time to Breakeven | 17 days | 6 days |
In The Past
Precipio's stock fell -45.9% during the 2025 US Tariff Shock. Such a loss loss requires a 84.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | PRPO | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -45.9% | -18.8% |
| % Gain to Breakeven | 84.8% | 23.1% |
| Time to Breakeven | 42 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -59.9% | -6.7% |
| % Gain to Breakeven | 149.3% | 7.1% |
| Time to Breakeven | 800 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -65.9% | -33.7% |
| % Gain to Breakeven | 193.1% | 50.9% |
| Time to Breakeven | 114 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -62.0% | -19.2% |
| % Gain to Breakeven | 163.4% | 23.8% |
| Time to Breakeven | 109 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -92.6% | -3.7% |
| % Gain to Breakeven | 1243.3% | 3.9% |
| Time to Breakeven | 17 days | 6 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -33.8% | -15.4% |
| % Gain to Breakeven | 51.2% | 18.2% |
| Time to Breakeven | 125 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -60.4% | -53.4% |
| % Gain to Breakeven | 152.4% | 114.4% |
| Time to Breakeven | 58 days | 1085 days |
In The Past
Precipio's stock fell -45.9% during the 2025 US Tariff Shock. Such a loss loss requires a 84.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Precipio (PRPO)
Precipio, Inc. (PRPO) is a healthcare solutions company that provides diagnostic products, reagents, and services, primarily in the United States. The company's core focus lies in offering diagnostic blood cancer testing services, aiming to improve the accuracy and speed of identifying these conditions.
Precipio's key offerings include several proprietary technologies. These encompass IV-Cell, a unique cell culture media for hematopoietic cell lineages; HemeScreen, a suite of genetic diagnostic panels for blood cancers; and ICE-COLD PCR, a patented specimen technology designed to significantly increase the sensitivity of molecular-based tests. The company also developed COVID-19 antibody tests and sells ICE-COLD PCR technology kits directly to bio-pharma customers.
The primary customers for Precipio's services are individuals requiring diagnostic blood cancer testing. Beyond direct testing services, the company serves the bio-pharma industry by providing its ICE-COLD PCR technology kits. Precipio also actively collaborates with academic institutions specializing in cancer research, diagnostics, and treatment, further integrating its solutions within the broader medical and research communities across the United States.
AI Analysis | Feedback
1. Precipio is like a specialized Quest Diagnostics or LabCorp, focusing on advanced diagnostic testing for blood cancers.
2. Precipio is like Exact Sciences, but dedicated to blood cancer diagnostics, offering both testing services and proprietary technologies.
3. Precipio is like a niche Illumina or Thermo Fisher Scientific, developing specialized molecular diagnostic technologies and reagents for blood cancer.
AI Analysis | Feedback
- Diagnostic blood cancer testing services: Precipio provides specialized services for diagnosing blood cancers.
- IV-Cell: A proprietary cell culture media designed for the simultaneous culturing of four hematopoietic cell lineages.
- HemeScreen: A suite of robust genetic diagnostic panels used for advanced testing.
- ICE-COLD PCR: A proprietary and patented specimen technology that enhances the sensitivity of molecular-based tests, also sold as kits to bio-pharma customers.
- COVID-19 antibody tests: Tests offered to detect antibodies for the COVID-19 virus.
AI Analysis | Feedback
Precipio (PRPO) primarily sells its diagnostic products, reagents, and services to other companies and institutions, rather than directly to individuals. Based on the provided description, its major customers fall into the following categories:
- Bio-pharma companies: Precipio sells its ICE-COLD-PCR technology kits to customers within the bio-pharmaceutical industry.
- Academic institutions: The company has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, indicating these institutions are recipients of its technologies and services.
- Healthcare providers and diagnostic laboratories: Precipio provides diagnostic blood cancer testing services, IV-Cell (cell culture media), HemeScreen (genetic diagnostic panels), and COVID-19 antibody tests. These types of products and services are typically utilized by hospitals, clinics, and reference laboratories for patient diagnosis and research.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
-
Challenges in Achieving Sustained Profitability and Financial Stability: Precipio has historically faced recurring operating losses, leading to "going concern" disclosures in financial audits. While the company has made strides in improving its financial health, including debt reduction and enhanced cash flow from operations, it has not yet achieved consistent GAAP net profitability and reported a net loss in Q3 2025. The company's Altman Z-Score, which assesses the likelihood of financial distress, places it in the "distress zone". Furthermore, Precipio's relatively small market capitalization contributes to high stock volatility and liquidity risks.
-
Regulatory and Technological Risks in the Diagnostics Industry: Operating in the highly regulated healthcare sector, Precipio is exposed to significant regulatory and technological risks. Evolving regulations, such as potential FDA rulings on Laboratory Developed Tests (LDTs), could necessitate costly product submission for approval. The development and commercialization of diagnostic products also involve inherent product liability risks, including claims arising from inaccurate test results that could lead to adverse health outcomes for patients. Additionally, like all healthcare companies handling sensitive data, Precipio faces cybersecurity and data privacy concerns, as evidenced by a 2024 incident involving its clearinghouse service, Change Healthcare, which impacted cash inflows, although the advance received has since been repaid.
-
Intense Competition and Limited Market Penetration: Precipio operates in a highly competitive cancer diagnostics market with numerous established and emerging players. The company's estimated market share remains under 1% of its total addressable market. This competitive landscape requires continuous innovation and effective market strategies to differentiate its proprietary technologies and services, such as IV-Cell, HemeScreen, and ICE-COLD PCR, and to gain wider adoption against a diverse range of competitors.
AI Analysis | Feedback
The rapid development and increasing commercialization of multi-cancer early detection (MCED) tests and advanced liquid biopsy platforms pose an emerging threat. These technologies aim to detect multiple types of cancer, often including blood cancers, from a single blood sample with high sensitivity and specificity, potentially much earlier than current methods. If these comprehensive, non-invasive tests gain widespread adoption for screening and early diagnosis, they could significantly disrupt the market for Precipio's more targeted diagnostic blood cancer testing services and genetic panels (HemeScreen) by offering a broader, potentially earlier, and less invasive diagnostic approach from competing large diagnostic and pharma companies.
AI Analysis | Feedback
Precipio, Inc. (NASDAQ: PRPO) operates in several key diagnostic markets. The addressable market sizes for its main products and services are outlined below:
- Diagnostic Blood Cancer Testing Services: The global blood cancer diagnostics market was estimated at approximately USD 10.83 billion in 2024 and is projected to grow to about USD 16.04 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 6.87% from 2025 to 2030. In the United States alone, this market was valued at USD 4.56 billion in 2024 and is predicted to reach around USD 9.04 billion by 2034, with a CAGR of 7.08% from 2025 to 2034. North America held the largest share of the global blood cancer diagnostics market, accounting for 37.7% in 2024.
- IV-Cell (Cell Culture Media): The global cell culture media market, which includes products like IV-Cell, was valued at USD 7.69 billion in 2025 and is expected to reach approximately USD 20.32 billion by 2034, expanding at a CAGR of 11.45% during the forecast period from 2025 to 2034. North America holds the largest revenue share in the cell culture media market, accounting for 38.21% in 2024.
- HemeScreen (Genetic Diagnostic Panels): The global gene panel market, encompassing genetic diagnostic panels such as HemeScreen, was valued at USD 4.85 billion in 2024. It is anticipated to grow to approximately USD 25.17 billion by 2034, exhibiting a CAGR of 17.9% from 2025 to 2034. North America dominated the global gene panel market with a 37% share in 2024, with the U.S. accounting for 72% of the North American market.
- ICE-COLD PCR (Molecular Diagnostics/PCR Technologies): ICE-COLD PCR is a proprietary specimen technology that increases the sensitivity of molecular-based tests. The broader global PCR technologies market was approximately USD 16.90 billion in 2025 and is projected to reach about USD 31.39 billion by 2034, with a CAGR of 7.12% from 2025 to 2034. North America led this market with a 44% share in 2024. The U.S. molecular diagnostics market, which includes PCR technologies, was valued at USD 8.93 billion in 2026 and is projected to reach USD 14.32 billion by 2031.
- COVID-19 Antibody Tests: Precipio launched a COVID-19 rapid antibody test in May 2021. The global COVID-19 antibody detection kit market is projected to reach USD 5.67 billion by 2025, with an anticipated CAGR of 6.9%. North America and Europe together account for approximately USD 10 billion of the global antibody detection kit market. The U.S. COVID-19 detection point-of-care (POC) kits market generated USD 975.2 million in 2022 and is expected to reach USD 769.2 million by 2030, with a negative CAGR of -2.9% from 2023 to 2030.
AI Analysis | Feedback
Precipio, Inc. (PRPO) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market dynamics:
- Continued Growth in Pathology Services Division: Precipio has demonstrated consistent revenue growth in its Pathology Services Division, with a significant increase in test volume and the adoption of its services by new physicians. For example, in Q3 2025, the Pathology Services Division's revenue increased by 20% quarter-over-quarter, reaching $6 million. Similarly, Q1 2025 saw a 54% year-over-year revenue growth and a 46% increase in test volume for this division, accompanied by 11 new ordering physicians utilizing their services. The company expects pathology division margins to stabilize in the mid-40% range with continued volume increases, further contributing to profitability that can be reinvested into growth.
- Expansion of the Product Division through New Offerings and Customer Acquisition: The Product Division is a significant growth area, driven by the launch of new diagnostic panels and the onboarding of new customers. In Q1 2025, Precipio successfully introduced two new panels and acquired a new customer, with expectations for increased orders. Additionally, two existing customers commenced validations for four new panels. The Product Division's revenue grew by 16% quarter-over-quarter in Q3 2025.
- Expanded Reimbursement and Favorable Regulatory Environment: Key regulatory and reimbursement developments are poised to positively impact revenue. The MolDx approval for Next-Generation Sequencing (NGS) testing is anticipated to boost future Medicare revenue. Furthermore, the reversal of the FDA ruling on Laboratory Developed Tests (LDTs) has removed a prior barrier for some laboratories, which is expected to increase future engagement and adoption of Precipio's products and services.
- Increased Market Penetration and Customer Acquisition: Precipio is focused on broadening its customer base through enhanced distributor relationships and expanded technical support capabilities. Management anticipates that several additional customers will come online in the upcoming quarters, contributing to sustained double-digit growth across both its Pathology Services and Product divisions.
- Operational Efficiencies and Margin Expansion: While not a direct revenue driver, the company's focus on improving operational efficiencies and expanding gross margins is critical for sustainable growth. Precipio's overall gross margins improved to 44% in Q3 2025 from 43% in Q2 2025 and are expected to exceed 50% by mid-2026. This improved profitability allows for greater reinvestment in growth initiatives and strengthens the company's financial position, indirectly fueling future revenue generation.
AI Analysis | Feedback
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Precipio Earnings Notes | 12/16/2025 | |
| Precipio Stock Lost 5.1%, Buy Or Wait? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 22.18 |
| Mkt Cap | 1.2 |
| Rev LTM | 787 |
| Op Inc LTM | -71 |
| FCF LTM | -14 |
| FCF 3Y Avg | -34 |
| CFO LTM | 2 |
| CFO 3Y Avg | -7 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.2% |
| Rev Chg 3Y Avg | 9.1% |
| Rev Chg Q | 6.7% |
| QoQ Delta Rev Chg LTM | 1.6% |
| Op Inc Chg LTM | 17.8% |
| Op Inc Chg 3Y Avg | 19.6% |
| Op Mgn LTM | -9.1% |
| Op Mgn 3Y Avg | -17.1% |
| QoQ Delta Op Mgn LTM | -0.0% |
| CFO/Rev LTM | 1.6% |
| CFO/Rev 3Y Avg | -3.1% |
| FCF/Rev LTM | -1.7% |
| FCF/Rev 3Y Avg | -6.5% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Third party payers | 12 | 9 | |||
| Medicare | 10 | 6 | |||
| Product revenue | 3 | 3 | 3 | 1 | 1 |
| Contract diagnostics and other | 0 | 0 | |||
| Medicaid | 0 | 0 | |||
| Self-pay | 0 | 0 | |||
| Adjustment for allowance for credit losses | -0 | -0 | |||
| Service revenue, net, less allowance for credit loss | 12 | 8 | 8 | ||
| Total | 24 | 19 | 15 | 9 | 9 |
| $ Mil | 2004 | 2003 | 2002 |
|---|---|---|---|
| Bio-Systems | -2 | -3 | -9 |
| Corporate | -9 | ||
| Nucleic Acids | -18 | -12 | -1 |
| Total | -29 | -15 | -10 |
| $ Mil | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|
| Lab Services | 23 | 22 | 25 | ||
| Genetic Assays and Platforms | 7 | 9 | |||
| Clinical Laboratories | 27 | 22 | |||
| Diagnostic Tools | 10 | 10 | |||
| Pharmacogenomic Services | 2 | 2 | |||
| Instrument Business | 7 | ||||
| Total | 30 | 30 | 39 | 34 | 32 |
Price Behavior
| Market Price | $23.80 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 07/18/2000 | |
| Distance from 52W High | -26.5% | |
| 50 Days | 200 Days | |
| DMA Price | $24.94 | $23.85 |
| DMA Trend | up | down |
| Distance from DMA | -4.6% | -0.2% |
| 3M | 1YR | |
| Volatility | 58.8% | 68.1% |
| Downside Capture | 92.16 | 57.19 |
| Upside Capture | 1.82 | 93.66 |
| Correlation (SPY) | 15.0% | 6.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.15 | 0.23 | 0.64 | 0.51 | 0.21 | 0.25 |
| Up Beta | 2.53 | 1.37 | 0.21 | -0.50 | -0.77 | 0.53 |
| Down Beta | 1.09 | 0.45 | -0.13 | -0.22 | 0.13 | -0.01 |
| Up Capture | -33% | -82% | 78% | 115% | 114% | 16% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 11 | 17 | 29 | 59 | 118 | 344 |
| Down Capture | -129% | 55% | 146% | 115% | 21% | 2% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 10 | 23 | 33 | 64 | 130 | 382 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PRPO | |
|---|---|---|---|---|
| PRPO | 51.3% | 68.0% | 0.88 | - |
| Sector ETF (XLV) | 20.3% | 15.7% | 0.98 | 8.3% |
| Equity (SPY) | 22.1% | 12.5% | 1.31 | 5.4% |
| Gold (GLD) | 23.5% | 27.8% | 0.75 | 4.1% |
| Commodities (DBC) | 23.6% | 18.7% | 0.99 | 4.0% |
| Real Estate (VNQ) | 13.4% | 13.9% | 0.67 | -1.3% |
| Bitcoin (BTCUSD) | -42.5% | 42.8% | -1.17 | 18.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PRPO | |
|---|---|---|---|---|
| PRPO | -18.7% | 74.8% | 0.04 | - |
| Sector ETF (XLV) | 6.5% | 14.9% | 0.25 | 9.2% |
| Equity (SPY) | 13.4% | 17.1% | 0.61 | 14.3% |
| Gold (GLD) | 17.8% | 18.3% | 0.79 | -1.6% |
| Commodities (DBC) | 7.3% | 19.5% | 0.27 | 6.6% |
| Real Estate (VNQ) | 2.9% | 18.9% | 0.05 | 10.3% |
| Bitcoin (BTCUSD) | 13.8% | 53.4% | 0.44 | 11.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PRPO | |
|---|---|---|---|---|
| PRPO | -41.0% | 450.2% | 0.39 | - |
| Sector ETF (XLV) | 10.3% | 16.6% | 0.51 | 1.6% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 2.6% |
| Gold (GLD) | 11.6% | 16.1% | 0.59 | -1.1% |
| Commodities (DBC) | 6.0% | 18.0% | 0.26 | 4.7% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.21 | 1.9% |
| Bitcoin (BTCUSD) | 58.6% | 66.2% | 0.99 | -0.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/15/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/27/2026 | 2.5% | 10.2% | -0.8% |
| 5/15/2025 | 10.2% | 36.4% | 52.2% |
| 2/28/2022 | -2.6% | -2.6% | -11.8% |
| 7/28/2021 | 0.7% | -2.0% | 19.8% |
| 7/22/2020 | -11.6% | -16.3% | 85.0% |
| SUMMARY STATS | |||
| # Positive | 3 | 2 | 3 |
| # Negative | 2 | 3 | 2 |
| Median Positive | 2.5% | 23.3% | 52.2% |
| Median Negative | -7.1% | -2.6% | -6.3% |
| Max Positive | 10.2% | 36.4% | 85.0% |
| Max Negative | -11.6% | -16.3% | -11.8% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/27/2026 | 2.5% | 10.2% | -0.8% |
| 5/15/2025 | 10.2% | 36.4% | 52.2% |
| 2/28/2022 | -2.6% | -2.6% | -11.8% |
| 7/28/2021 | 0.7% | -2.0% | 19.8% |
| 7/22/2020 | -11.6% | -16.3% | 85.0% |
| SUMMARY STATS | |||
| # Positive | 3 | 2 | 3 |
| # Negative | 2 | 3 | 2 |
| Median Positive | 2.5% | 23.3% | 52.2% |
| Median Negative | -7.1% | -2.6% | -6.3% |
| Max Positive | 10.2% | 36.4% | 85.0% |
| Max Negative | -11.6% | -16.3% | -11.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/14/2026 | 10-Q |
| 12/31/2025 | 03/30/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/29/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/14/2026 | 10-Q |
| 12/31/2025 | 03/30/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/29/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/11/2022 | 10-Q |
| 12/31/2021 | 03/30/2022 | 10-K |
| 09/30/2021 | 11/12/2021 | 10-Q |
| 06/30/2021 | 08/12/2021 | 10-Q |
| 03/31/2021 | 05/14/2021 | 10-Q |
| 12/31/2020 | 03/29/2021 | 10-K |
| 09/30/2020 | 11/13/2020 | 10-Q |
| 06/30/2020 | 08/13/2020 | 10-Q |
| 03/31/2020 | 05/14/2020 | 10-Q |
| 12/31/2019 | 03/27/2020 | 10-K |
| 09/30/2019 | 11/13/2019 | 10-Q |
| 06/30/2019 | 08/09/2019 | 10-Q |
Insider Activity
Updated 5/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sandberg, Richard A | Wythburn Associates, Ltd, 94% owned jointly by reporting person and spouse | Sell | 5262026 | 25.02 | 900 | 22,517 | 75,058 | Form | |
| 2 | Sandberg, Richard A | Wythburn Associates, Ltd, 94% owned jointly by reporting person and spouse | Sell | 5212026 | 25.00 | 500 | 12,500 | 97,500 | Form | |
| 3 | Sandberg, Richard A | Direct | Sell | 5212026 | 24.89 | 2,034 | 50,632 | 202,677 | Form | |
| 4 | Sandberg, Richard A | Wythburn Associates, Ltd, 94% owned jointly by reporting person and spouse | Sell | 5212026 | 24.42 | 600 | 14,652 | 107,451 | Form | |
| 5 | Sabet, Ahmed Zaki | Chief Operating Officer | Direct | Buy | 4102026 | 27.93 | 19 | 531 | 28,880 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sandberg, Richard A | Wythburn Associates, Ltd, 94% owned jointly by reporting person and spouse | Sell | 5262026 | 25.02 | 900 | 22,517 | 75,058 | Form | |
| 2 | Sandberg, Richard A | Wythburn Associates, Ltd, 94% owned jointly by reporting person and spouse | Sell | 5212026 | 25.00 | 500 | 12,500 | 97,500 | Form | |
| 3 | Sandberg, Richard A | Direct | Sell | 5212026 | 24.89 | 2,034 | 50,632 | 202,677 | Form | |
| 4 | Sandberg, Richard A | Wythburn Associates, Ltd, 94% owned jointly by reporting person and spouse | Sell | 5212026 | 24.42 | 600 | 14,652 | 107,451 | Form | |
| 5 | Sabet, Ahmed Zaki | Chief Operating Officer | Direct | Buy | 4102026 | 27.93 | 19 | 531 | 28,880 | Form |
| 6 | Sabet, Ahmed Zaki | Chief Operating Officer | Direct | Buy | 1062026 | 23.40 | 20 | 468 | 17,199 | Form |
| 7 | Sabet, Ahmed Zaki | Chief Operating Officer | Direct | Buy | 11202025 | 19.50 | 25 | 488 | 13,942 | Form |
| 8 | Sabet, Ahmed Zaki | Chief Operating Officer | Direct | Buy | 11202025 | 16.30 | 31 | 505 | 11,247 | Form |
| 9 | Laporte, Kathleen | Direct | Sell | 9102025 | 20.06 | 6,152 | 123,409 | 123,389 | Form | |
| 10 | Sandberg, Richard A | Wythburn Associates, Ltd, 94% owned jointly by reporting person and spouse | Buy | 5302025 | 10.00 | 1,399 | 13,986 | 401,621 | Form | |
| 11 | Sandberg, Richard A | Wythburn Associates, Ltd, 94% owned jointly by reporting person and spouse | Buy | 5282025 | 9.80 | 101 | 990 | 380,005 | Form | |
| 12 | Sandberg, Richard A | Wythburn Associates, Ltd, 94% owned jointly by reporting person and spouse | Buy | 5272025 | 9.33 | 500 | 4,665 | 360,838 | Form | |
| 13 | Sandberg, Richard A | Roth IRA for the benefit of Richard A Sandberg | Buy | 5222025 | 9.25 | 5,035 | 46,574 | 325,369 | Form | |
| 14 | Sandberg, Richard A | Wythburn Associates, Ltd, 94% owned jointly by reporting person and spouse | Buy | 5222025 | 9.30 | 3,000 | 27,900 | 355,028 | Form | |
| 15 | Sandberg, Richard A | Roth IRA for the benefit of Richard A Sandberg | Buy | 5212025 | 8.47 | 4,251 | 36,006 | 255,286 | Form | |
| 16 | Sandberg, Richard A | Roth IRA for the benefit of Richard A Sandberg | Buy | 5212025 | 8.21 | 714 | 5,862 | 212,549 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.